A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.
News|Articles|June 25, 2026
CGMs, Automated Insulin Delivery Support Personalized Diabetes Treatment
Author(s)Ashley Gallagher, MA
Pharmacists leverage CGM and automated insulin delivery to personalize diabetes care, prevent errors, and expand equitable access to technology.
Advertisement
Advertisement
The landscape of diabetes care is undergoing a transformation as fingersticks and episodic monitoring give way to real-time data and automated logic. For pharmacists, this evolution represents a shift toward a more proactive, data-driven role in patient management. At the heart of this shift are continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems, technologies that are moving from specialized tools for the few to routine components of care for the many.1,2
Related to this article
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
In a review of records assessing patients with type 2 diabetes, researchers provide a comprehensive detail of strategies leading to diabetes remission though gaps persist.
Exploring the effects of weight-loss and GLP-1 therapies, researchers determine the specific metabolic determinants that lead to patients’ weight reduction.
The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.
Advertisement
Advertisement